Switzerland | Imports and Exports | World | Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products | Value (US$) and Value Growth, YoY (%) | 2012 - 2023
The value of exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Switzerland totalled $ 52 billion in 2023. Sales of commodity group 3002 from Switzerland went up by 4.76% compared to 2022: exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" went up by $ 2.38 billion (cumulative exports of commodity group 3002 from Switzerland amounted $50 billion in 2022)
Exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" amounted to 12.4% of total exports from Switzerland (cumulative merchandise exports from Switzerland totalled $ 419 billion in 2023). The share of commodity group 3002 in total exports from Switzerland decreased by 0.023 p.p. compared to 2022 (it was 12.5% in 2022 and cumulative exports from Switzerland were equal to $ 400 billion).
Exports of commodity group 3002 amounted to 52% of total sales of group "" from Switzerland in 2023 (the value of exports of commodity group from Switzerland amounted to $99 billion in 2023). The share of exports of commodity group 3002 in sales of commodity group from Switzerland increased by 1.9 p.p. compared to 2022 (it was 51% in 2022, and exports of commodity group from Switzerland were $98 billion).
Where does Switzerland export Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc?
Top export destinations of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Switzerland in 2023:
- USA with a share of 32% (17 billion US$)
- Germany with a share of 14.5% (7.65 billion US$)
- China with a share of 5.82% (3.05 billion US$)
- France with a share of 4.15% (2.18 billion US$)
- Japan with a share of 3.81% (2 billion US$)
- Canada with a share of 3.35% (1.76 billion US$)
- Belgium with a share of 3.33% (1.75 billion US$)
- United Kingdom with a share of 2.99% (1.57 billion US$)
- Italy with a share of 2.72% (1.42 billion US$)
- Spain with a share of 2.21% (1.16 billion US$)
Exports structure of 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc - from Switzerland in 2023 represented by the following main commodity groups:
- 0.132% (69 million US$): 300290 - Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & sim. products
The value of imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" to Switzerland totalled $ 17.5 billion in 2023. Sales of commodity group 3002 to Switzerland went up by 7.98% compared to 2022: imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" went up by $ 1.29 billion (the value of imports of commodity group 3002 to Switzerland was equal to $16.2 billion in 2022)
Imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" accounted for 4.79% of total import flow to Switzerland (in 2023, total imports to Switzerland amounted to $ 365 billion). The share of commodity group 3002 in total imports to Switzerland increased by 0.24 p.p. compared to 2022 (it was 4.55% in 2022 and cumulative imports to Switzerland were equal to $ 356 billion).
Imports of commodity group 3002 reached 29% of total imports of group "" to Switzerland in 2023 (imports of commodity group to Switzerland totalled $58 billion in 2023). The share of purchases of commodity group 3002 in imports of commodity group to Switzerland went down by 3.35 p.p. compared to 2022 (it was 33% in 2022, and imports of commodity group to Switzerland accounted for $48 billion).
Where does Switzerland import Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc from?
Top trading partners (import of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc") of Switzerland in 2023:
- USA with a share of 22% (3.97 billion US$)
- Germany with a share of 21% (3.81 billion US$)
- Ireland with a share of 18.2% (3.19 billion US$)
- Korea with a share of 8.86% (1.55 billion US$)
- Japan with a share of 8.17% (1.43 billion US$)
- Singapore with a share of 4.41% (772 million US$)
- Belgium with a share of 2.81% (492 million US$)
- Denmark with a share of 2.15% (377 million US$)
- France with a share of 2.09% (367 million US$)
- Netherlands with a share of 2.04% (357 million US$)
Imports structure of 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc - to Switzerland in 2023 represented by the following main commodity groups:
- 0.226% (39 million US$): 300290 - Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & sim. products
